Brand
LAZCLUZE
LAZCLUZE is an oral EGFR inhibitor for non-small cell lung cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it with RYBREVANT as a key Innovative Medicine product.
Documented stakes
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission